PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 9, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dan Wildman to its Board of Directors, effective
Conference Call and Webcast Scheduled for Thursday, November 10, 2022 at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
-- UGN-102 is an Investigational Formulation of the Novel RTGel™ Delivery Technology Combined with Mitomycin in Phase 3 Development for the Treatment of Low-Grade Intermediate Risk NMIBC -- -- Webinar scheduled for Tuesday October 18, 2022 at 9:00 AM ET -- PRINCETON, N.J. --(BUSINESS WIRE)--Oct.
-- This Extension Increases Flexibility and Efficiency for Customers and Patients -- PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 28, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 12, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dr. Leana S.
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 9, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 10 new
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 7, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences in
Reported Jelmyto® net product revenue of $16.6 million , a 22% increase from the first quarter of 2022, and 28% increase YoY; reaffirmed 2022 full-year revenue guidance of $70-$80 million Enrollment of UGN-102 Phase 3 single-arm, ENVISION pivotal trial in subjects with low-grade intermediate risk
Conference Call and Webcast Scheduled for Thursday, August 11, 2022 at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 27, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) and options
